Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Curcumin - Vascarta

Next Previous
Drug Profile

Curcumin - Vascarta

Alternative Names: VAS-101 -Vascarta; Vasceptor®

Latest Information Update: 27 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albert Einstein College of Medicine
  • Developer Vascarta
  • Class Analgesics; Anti-ischaemics; Antianaemics; Antidementias; Antihistamines; Antihypertensives; Antineoplastics; Antivirals; Catechols; Chemopreventatives; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CCR2 receptor antagonists; Chemokine CCL5 inhibitors; Cyclo-oxygenase 2 inhibitors; Cystic fibrosis transmembrane conductance regulator modulators; HIV integrase inhibitors; Interleukin 1beta inhibitors; Interleukin 6 inhibitors; Interleukin 8 inhibitors; Mast cell stabilisers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sickle cell anaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase I Osteoarthritis; Sickle cell anaemia
  • Preclinical Dementia; Hypertension; Pain; Sarcopenia

Most Recent Events

  • 25 Aug 2026 Vascarta has patent protection for Vasporta™ gel-based delivery platform
  • 25 Aug 2026 Preclinical trials in Pain in USA (unspecified route) prior to August 2026
  • 25 Aug 2026 Pharmacodynamics data from a preclinical study in Sickle-cell disease released by Vascarta

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top